• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

组织型纤溶酶原激活剂对猫急性心肌缺血的有益作用。

Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats.

作者信息

Darius H, Yanagisawa A, Brezinski M E, Hock C E, Lefer A M

出版信息

J Am Coll Cardiol. 1986 Jul;8(1):125-31. doi: 10.1016/s0735-1097(86)80102-4.

DOI:10.1016/s0735-1097(86)80102-4
PMID:3086417
Abstract

Tissue-type plasminogen activator is a new thrombolytic agent that dissolves intravascular thrombi in coronary and peripheral vessels with less pronounced systemic lysis than that produced by streptokinase. Plasminogen activator was shown to induce reperfusion, and to salvage ischemic myocardium, by lysing experimentally induced coronary artery thrombi. The effect of a melanoma cell-derived tissue-type plasminogen activator was studied in cat myocardium rendered ischemic by coronary artery ligation for 2 hours and reperfused for another 4 hours. Plasminogen activator was infused at a rate of 500 IU X kg-1 X min-1 for the first 30 minutes of reperfusion. The marked increase in plasma creatine kinase activity during reperfusion was significantly lower in plasminogen activator-treated cats at 4, 5 and 6 hours, with 7.7 +/- 1.5 X 10(-3) IU X mg protein-1 (n = 8) in the plasminogen activator group versus 17.8 +/- 3.5 X 10(-3) IU X mg protein-1 (n = 7) in the vehicle group at 6 hours (mean +/- SEM). The area at risk in the two ischemic groups was not different, being 14.6 +/- 1.5 and 16.6 +/- 1.4% of total left ventricular mass for the treated and untreated groups, respectively. However, the mass of necrotic tissue determined histochemically was significantly lower in the plasminogen activator-treated group, accounting for 29.5 +/- 3.9% of the area at risk compared with 46.8 +/- 4.2% of area at risk in cats receiving only the vehicle (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

组织型纤溶酶原激活剂是一种新型溶栓剂,它能溶解冠状动脉和外周血管内的血栓,与链激酶相比,全身溶栓作用较弱。通过溶解实验诱导的冠状动脉血栓,纤溶酶原激活剂被证明可诱导再灌注并挽救缺血心肌。研究了黑色素瘤细胞衍生的组织型纤溶酶原激活剂对冠状动脉结扎2小时并再灌注4小时的猫心肌的作用。在再灌注的前30分钟,以500 IU·kg-1·min-1的速率输注纤溶酶原激活剂。再灌注期间血浆肌酸激酶活性的显著升高在纤溶酶原激活剂治疗的猫中,在4、5和6小时时显著降低,纤溶酶原激活剂组在6小时时为7.7±1.5×10(-3) IU·mg蛋白-1(n = 8),而载体组为17.8±3.5×10(-3) IU·mg蛋白-1(n = 7)(平均值±标准误)。两个缺血组的危险面积无差异,治疗组和未治疗组分别占左心室总质量的14.6±1.5%和16.6±1.4%。然而,组织化学测定的坏死组织质量在纤溶酶原激活剂治疗组中显著较低,占危险面积的29.5±3.9%,而仅接受载体的猫中为危险面积的46.8±4.2%(p<0.02)。(摘要截短于250字)

相似文献

1
Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats.组织型纤溶酶原激活剂对猫急性心肌缺血的有益作用。
J Am Coll Cardiol. 1986 Jul;8(1):125-31. doi: 10.1016/s0735-1097(86)80102-4.
2
Potentiation of myocardial salvage by tissue type plasminogen activator in combination with a thromboxane synthetase inhibitor in ischemic cat myocardium.组织型纤溶酶原激活剂与血栓素合成酶抑制剂联合应用对缺血猫心肌的心肌挽救作用增强。
Circ Res. 1988 Sep;63(3):621-7. doi: 10.1161/01.res.63.3.621.
3
Endothelium and myocardial protecting actions of taprostene, a stable prostacyclin analogue, after acute myocardial ischemia and reperfusion in cats.稳定前列环素类似物他前列烯在猫急性心肌缺血再灌注后的内皮及心肌保护作用
Circ Res. 1990 May;66(5):1362-70. doi: 10.1161/01.res.66.5.1362.
4
Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.氧自由基清除剂在犬冠状动脉溶栓模型中作为组织型纤溶酶原激活剂辅助治疗的研究
Cardiovasc Res. 1993 Jun;27(6):925-34. doi: 10.1093/cvr/27.6.925.
5
Reduction in myocardial ischemic/reperfusion injury and neutrophil accumulation after therapeutic administration of streptokinase.链激酶治疗后心肌缺血/再灌注损伤及中性粒细胞聚集减少。
J Cardiovasc Pharmacol. 1991 Nov;18(5):729-38. doi: 10.1097/00005344-199111000-00011.
6
Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.重组组织型纤溶酶原激活剂初始溶栓后通过维持微血管通畅增强心肌挽救。
Cardiovasc Res. 1990 Sep;24(9):697-706. doi: 10.1093/cvr/24.9.697.
7
S-nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium.S-亚硝基化组织型纤溶酶原激活剂对猫心肌缺血/再灌注损伤的保护作用:内皮的作用
J Pharmacol Exp Ther. 1996 Dec;279(3):1174-80.
8
Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi?组织型纤溶酶原激活剂除了具有溶解冠状动脉内血栓的能力外,对心肌是否有直接的有益作用?
Circulation. 1989 May;79(5):1125-36. doi: 10.1161/01.cir.79.5.1125.
9
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Circulation. 1984 Oct;70(4):700-7. doi: 10.1161/01.cir.70.4.700.
10
Status of the myocardium and infarct-related coronary artery in 19 necropsy patients with acute recanalization using pharmacologic (streptokinase, r-tissue plasminogen activator), mechanical (percutaneous transluminal coronary angioplasty) or combined types of reperfusion therapy.
J Am Coll Cardiol. 1987 Apr;9(4):785-801. doi: 10.1016/s0735-1097(87)80234-6.

引用本文的文献

1
Thrombolytic-Enhanced Extracorporeal Cardiopulmonary Resuscitation After Prolonged Cardiac Arrest.长时间心脏骤停后溶栓增强的体外心肺复苏
Crit Care Med. 2016 Feb;44(2):e58-69. doi: 10.1097/CCM.0000000000001305.
2
Bolus thrombolytic infusion during prolonged refractory cardiac arrest of undiagnosed cause.在病因未明的长时间难治性心脏骤停期间进行大剂量溶栓输注。
Emerg Med J. 2006 Mar;23(3):e19. doi: 10.1136/emj.2005.029132.
3
Late potentials as predictors of risk after thrombolytic treatment?溶栓治疗后晚期电位作为风险预测指标?
Br Heart J. 1990 Sep;64(3):174-6. doi: 10.1136/hrt.64.3.174.